Literature DB >> 8330927

Intravenous zymosan-A challenge induces an alveolar inflammatory response.

R T Sawyer1.   

Abstract

The purpose of this study was to evaluate the ability of intravenous zymosan-A (ZyA) challenge to induce an alveolar inflammatory response as indicated by inflammatory changes among lung lavage cells. The organ distribution of 1 mg of [51Cr]ZyA revealed that immediately following intravenous challenge of female ICR mice approximately 81% of the total cpm injected was associated with pulmonary tissue. Approximately 15% of the injected cpm was associated with the peripheral blood, liver, and spleen. ZyA translocated from the vascular compartment into pulmonary alveoli and was detected within polymorphonuclear neutrophils (PMN) and alveolar macrophages (AM) 18 h after intravenous challenge. PMN numbers among lung lavage cells increased beginning one day after challenge to a peak of approximately 5 x 10(5) PMNs by day 3 after challenge. The PMN response subsided by day 5 after challenge. There was no significant increase in the numbers of AM during the first week after intravenous ZyA; however, the number of AM increased from approximately 5 x 10(5) AM on day 1 after challenge to approximately 1.1 x 10(6) AM by day 5 after challenge. Within 24 h of intravenous ZyA, the number of AM in S phase of the cell cycle increased from approximately 2.5 x 10(4) AM one day after challenge to 1.1 x 10(5) AM in S phase five days after challenge. The data suggest that intravenous ZyA localized within pulmonary tissue immediately following intravenous challenge and translocated into the alveolar compartment where ZyA particles were found within phagocytes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8330927     DOI: 10.1007/bf00918990

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  26 in total

1.  Effect of zymosan on endotoxin toxicity in mice.

Authors:  B BENACERRAF; G J THORBECKE; D JACOBY
Journal:  Proc Soc Exp Biol Med       Date:  1959-04

2.  Alterations in serum properdin levels following injection of Zymosan.

Authors:  L PILLEMER; O A ROSS
Journal:  Science       Date:  1955-05-20       Impact factor: 47.728

3.  On the composition of zymosan.

Authors:  F J DI CARLO; J V FIORE
Journal:  Science       Date:  1958-04-04       Impact factor: 47.728

4.  Increase in bactericidal activity as a result of injection of zymosan.

Authors:  B BLATTBERG
Journal:  Proc Soc Exp Biol Med       Date:  1956 Aug-Sep

5.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

6.  [Distribution of C-14-labelled zymosan in the tissues of mice after intravenous administration].

Authors:  N L SAMOILINA
Journal:  Probl Gematol Pereliv Krovi       Date:  1962-06

7.  The significance of local resident pulmonary alveolar macrophage proliferation to population renewal.

Authors:  R T Sawyer
Journal:  J Leukoc Biol       Date:  1986-01       Impact factor: 4.962

8.  The percentage of monocytes among "mononuclear" cell fractions obtained from normal human blood.

Authors:  D Zucker-Franklin
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

9.  In vitro tumoricidal activity of resting and glucan-activated Kupffer cells.

Authors:  E R Sherwood; D L Williams; R B McNamee; E L Jones; I W Browder; N R Di Luzio
Journal:  J Leukoc Biol       Date:  1987-07       Impact factor: 4.962

10.  The cytokinetic behavior of pulmonary alveolar macrophages in monocytopenic mice.

Authors:  R T Sawyer
Journal:  J Leukoc Biol       Date:  1986-01       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.